PRODIVET PHARMACEUTICALS: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
PRODIVET PHARMACEUTICALS
Largest movements
- Cash +€147,388
up €147,388 (+11.9%), from €1.2m to €1.4m
mainly Depreciation (+€120,060) and Net result for the year (+€101,374)
- Tangible fixed assets -€72,343
down €72,343 (-20.6%), from €350,522 to €278,180
of which Furniture and vehicles: -€46,352
- Stocks and contracts +€69,747
up €69,747 (+15.0%), from €464,112 to €533,859
- Receivables within one year +€35,225
up €35,225 (+16.9%), from €208,149 to €243,375
of which Trade receivables: +€47,351
- Profit (loss) carried forward +€101,374
up €101,374 (+9.1%), from €1.1m to €1.2m
- Trade debts +€60,580
up €60,580 (+90.6%), from €66,892 to €127,472
- Gross operating margin -€220,042
down €220,042 (-20.3%), from €1.1m to €861,860
- Taxes -€80,868
down €80,868 (-66.6%), from €121,457 to €40,589
- Depreciation +€15,049
up €15,049 (+14.3%), from €105,011 to €120,060
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €3,160,249 | €3,319,683 | +€159,434 | +5.0% |
| Fixed assets | 21/28 | €630,144 | €528,434 | -€101,710 | -16.1% |
| Intangible fixed assets | 21 | €279,622 | €250,255 | -€29,368 | -10.5% |
| Tangible fixed assets | 22/27 | €350,522 | €278,180 | -€72,343 | -20.6% |
| Land and buildings | 22 | €104,796 | €99,378 | -€5,418 | -5.2% |
| Plant, machinery and equipment | 23 | €71,160 | €50,588 | -€20,572 | -28.9% |
| Furniture and vehicles | 24 | €174,566 | €128,214 | -€46,352 | -26.6% |
| Current assets | 29/58 | €2,530,104 | €2,791,248 | +€261,144 | +10.3% |
| Stocks and contracts in progress | 3 | €464,112 | €533,859 | +€69,747 | +15.0% |
| Stocks | 30/36 | €464,112 | €533,859 | +€69,747 | +15.0% |
| Amounts receivable within one year | 40/41 | €208,149 | €243,375 | +€35,225 | +16.9% |
| Trade receivables | 40 | €192,710 | €240,061 | +€47,351 | +24.6% |
| Other amounts receivable | 41 | €15,440 | €3,313 | -€12,126 | -78.5% |
| Current investments | 50/53 | €600,000 | €600,000 | = | 0.0% |
| Cash at bank and in hand | 54/58 | €1,241,971 | €1,389,359 | +€147,388 | +11.9% |
| Deferred charges and accrued income | 490/1 | €15,872 | €24,656 | +€8,784 | +55.3% |
| Total equity and liabilities | 10/49 | €3,160,249 | €3,319,683 | +€159,434 | +5.0% |
| Equity | 10/15 | €2,712,717 | €2,814,090 | +€101,374 | +3.7% |
| Contributions | 10/11 | €101,520 | €101,520 | = | 0.0% |
| Capital | 10 | €101,520 | €101,520 | = | 0.0% |
| Issued capital | 100 | €101,520 | €101,520 | = | 0.0% |
| Reserves | 13 | €1,491,152 | €1,491,152 | = | 0.0% |
| Non-distributable reserves | 130/1 | €10,152 | €10,152 | = | 0.0% |
| Legal reserve | 130 | €10,152 | €10,152 | = | 0.0% |
| Distributable reserves | 133 | €1,481,000 | €1,481,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €1,120,045 | €1,221,418 | +€101,374 | +9.1% |
| Amounts payable | 17/49 | €447,532 | €505,592 | +€58,060 | +13.0% |
| Amounts payable within one year | 42/48 | €433,916 | €493,943 | +€60,026 | +13.8% |
| Trade debts | 44 | €66,892 | €127,472 | +€60,580 | +90.6% |
| Suppliers | 440/4 | €66,892 | €127,472 | +€60,580 | +90.6% |
| Taxes, remuneration and social security | 45 | €179,487 | €168,601 | -€10,886 | -6.1% |
| Taxes | 450/3 | €108,815 | €111,858 | +€3,043 | +2.8% |
| Remuneration and social security | 454/9 | €70,672 | €56,743 | -€13,929 | -19.7% |
| Other amounts payable | 47/48 | €187,537 | €197,870 | +€10,333 | +5.5% |
| Accrued charges and deferred income | 492/3 | €13,616 | €11,650 | -€1,967 | -14.4% |
| Non-recurring operating income | 76A | €909 | - | -€909 | |
| Remuneration, social security and pensions | 62 | €581,783 | €573,683 | -€8,100 | -1.4% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €105,011 | €120,060 | +€15,049 | +14.3% |
| Other operating charges | 640/8 | €15,060 | €13,406 | -€1,653 | -11.0% |
| Non-recurring operating charges | 66A | - | €325 | +€325 | |
| Gross operating margin | 9900 | €1,081,902 | €861,860 | -€220,042 | -20.3% |
| Operating profit (loss) | 9901 | €380,048 | €154,385 | -€225,663 | -59.4% |
| Financial income | 75/76B | €20,776 | €11,673 | -€9,102 | -43.8% |
| Recurring financial income | 75 | €20,776 | €11,673 | -€9,102 | -43.8% |
| Financial charges | 65/66B | €28,300 | €24,095 | -€4,205 | -14.9% |
| Recurring financial charges | 65 | €28,300 | €24,095 | -€4,205 | -14.9% |
| Profit (loss) for the period before taxes | 9903 | €372,524 | €141,963 | -€230,561 | -61.9% |
| Income taxes | 67/77 | €121,457 | €40,589 | -€80,868 | -66.6% |
| Profit (loss) for the period | 9904 | €251,066 | €101,374 | -€149,692 | -59.6% |
| Profit (loss) for the period to be appropriated | 9905 | €251,066 | €101,374 | -€149,692 | -59.6% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 30 October 2026 via checked.be.